Stay updated with breaking news from Dermacyte Liquid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Image by Peggy und Marco Lachmann-Anke from Pixabay by Jim Shamp, NCBiotech Writer — May 27, 2021 . RESEARCH TRIANGLE PARK – Research Triangle Park regenerative wound-healing product developer Merakris Therapeutics is launching human testing of a liquid to treat open sores on the skin known as non-healing venous stasis ulcers (VSUs). Merakris has received U.S. Food and Drug Administration clearance for a Phase 2 clinical trial to test its investigational therapy, Dermacyte Amniotic Wound Care Liquid. The study will address the drug’s frequency of administration, safety and efficacy. ...